Industry to determine "least burdensome" FDA approval route
This article was originally published in Clinica
Executive Summary
The US FDA has promised to have a guidance document available in a matter of weeks that will interpret the crucial "least burdensome" clause of the FDA Modernization Act (FDAMA), officials said last week at the Medical Device Update conference sponsored by the Food and Drug Law Institute in Washington.